BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 25174961)

  • 1. Proposed strategy for the use of high-dose chemotherapy with stem cell rescue and intrathecal topotecan without whole-brain irradiation for infantile classic medulloblastoma.
    Yamada A; Moritake H; Kamimura S; Yamashita S; Takeshima H; Nunoi H
    Pediatr Blood Cancer; 2014 Dec; 61(12):2316-8. PubMed ID: 25174961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose chemotherapy with autologous stem cell rescue followed by posterior fossa irradiation for local medulloblastoma recurrence or progression after conventional chemotherapy.
    Ridola V; Grill J; Doz F; Gentet JC; Frappaz D; Raquin MA; Habrand JL; Sainte-Rose C; Valteau-Couanet D; Kalifa C
    Cancer; 2007 Jul; 110(1):156-63. PubMed ID: 17541945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose chemotherapy with autologous stem cell rescue for children with high risk and recurrent medulloblastoma and supratentorial primitive neuroectodermal tumors.
    Pérez-Martínez A; Lassaletta A; González-Vicent M; Sevilla J; Díaz MA; Madero L
    J Neurooncol; 2005 Jan; 71(1):33-8. PubMed ID: 15719272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose busulfan-thiotepa with autologous stem cell transplantation followed by posterior fossa irradiation in young children with classical or incompletely resected medulloblastoma.
    Bergthold G; El Kababri M; Varlet P; Dhermain F; Sainte-Rose C; Raquin MA; Kieffer V; Goma G; Grill J; Valteau-Couanet D; Dufour C
    Pediatr Blood Cancer; 2014 May; 61(5):907-12. PubMed ID: 24470384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose chemotherapy with autologous stem cell rescue as first line of treatment in young children with medulloblastoma and supratentorial primitive neuroectodermal tumors.
    Pérez-Martínez A; Quintero V; Vicent MG; Sevilla J; Díaz MA; Madero L
    J Neurooncol; 2004; 67(1-2):101-6. PubMed ID: 15072454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial.
    Gajjar A; Chintagumpala M; Ashley D; Kellie S; Kun LE; Merchant TE; Woo S; Wheeler G; Ahern V; Krasin MJ; Fouladi M; Broniscer A; Krance R; Hale GA; Stewart CF; Dauser R; Sanford RA; Fuller C; Lau C; Boyett JM; Wallace D; Gilbertson RJ
    Lancet Oncol; 2006 Oct; 7(10):813-20. PubMed ID: 17012043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Double high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation for primary disseminated medulloblastoma: a report of 3 cases.
    Aihara Y; Tsuruta T; Kawamata T; Kanno H; Maebayashi K; Sakauchi M; Wada E; Osawa M; Fujii H; Kubo O; Hori T
    J Pediatr Hematol Oncol; 2010 Mar; 32(2):e70-4. PubMed ID: 20168248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced-dose craniospinal radiotherapy followed by tandem high-dose chemotherapy and autologous stem cell transplantation in patients with high-risk medulloblastoma.
    Sung KW; Lim DH; Son MH; Lee SH; Yoo KH; Koo HH; Kim JH; Suh YL; Joung YS; Shin HJ
    Neuro Oncol; 2013 Mar; 15(3):352-9. PubMed ID: 23258845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategy to minimize radiation burden in infants and high-risk medulloblastoma using intrathecal methotrexate and high-dose chemotherapy: A prospective registry study in Japan.
    Yamasaki K; Okada K; Soejima T; Sakamoto H; Hara J
    Pediatr Blood Cancer; 2020 Jan; 67(1):e28012. PubMed ID: 31544362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose chemotherapy in children with newly-diagnosed medulloblastoma.
    Grill J; Dufour C; Kalifa C
    Lancet Oncol; 2006 Oct; 7(10):787-9. PubMed ID: 17012036
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment of adult nonmetastatic medulloblastoma patients according to the paediatric HIT 2000 protocol: a prospective observational multicentre study.
    Friedrich C; von Bueren AO; von Hoff K; Kwiecien R; Pietsch T; Warmuth-Metz M; Hau P; Deinlein F; Kuehl J; Kortmann RD; Rutkowski S
    Eur J Cancer; 2013 Mar; 49(4):893-903. PubMed ID: 23182688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk-adapted chemotherapy in childhood medulloblastoma.
    Varan A
    Expert Rev Anticancer Ther; 2011 May; 11(5):771-80. PubMed ID: 21554052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant chemotherapy after reduced craniospinal irradiation dose in children with average-risk medulloblastoma: a 5-year follow-up study.
    Wahba HA; Abu-Hegazy M; Wasel Y; Ismail EI; Zidan AS
    J BUON; 2013; 18(2):425-9. PubMed ID: 23818356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of advanced ovarian cancer.
    Donato ML; Gershenson DM; Wharton JT; Ippoliti CM; Aleman AS; Bodurka-Bevers D; Bevers MW; Burke TW; Levenback CF; Wolf JK; Freedman RS; Bast RC; Gajewski JL; Champlin RE
    Gynecol Oncol; 2001 Sep; 82(3):420-6. PubMed ID: 11520135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of reduced-dose craniospinal irradiation and combination chemotherapy for children with newly diagnosed medulloblastoma: A report from the Japanese Pediatric Brain Tumor Consortium.
    Okada K; Soejima T; Sakamoto H; Hirato J; Hara J
    Pediatr Blood Cancer; 2020 Nov; 67(11):e28572. PubMed ID: 32710713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medulloblastoma with myogenic differentiation: long-term survival in a patient treated with aggressive combination therapy and autologous stem cell transplantation.
    Rattenberry W; McDonough CH; Burger PC; Cohen KJ
    J Neurooncol; 2011 Dec; 105(3):659-62. PubMed ID: 21688181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three-year recurrence-free survival in a patient with recurrent medulloblastoma after resection, high-dose chemotherapy, and intrathecal Yttrium-90-labeled DOTA0-D-Phe1-Tyr3-octreotide radiopeptide brachytherapy.
    Beutler D; Avoledo P; Reubi JC; Mäcke HR; Müller-Brand J; Merlo A; Kühne T
    Cancer; 2005 Feb; 103(4):869-73. PubMed ID: 15641034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome and prognostic factors of desmoplastic medulloblastoma treated within a multidisciplinary treatment concept.
    Rieken S; Gaiser T; Mohr A; Welzel T; Witt O; Kulozik AE; Wick W; Debus J; Combs SE
    BMC Cancer; 2010 Aug; 10():450. PubMed ID: 20731859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of young children with localized medulloblastoma by chemotherapy alone: results of the prospective, multicenter trial HIT 2000 confirming the prognostic impact of histology.
    von Bueren AO; von Hoff K; Pietsch T; Gerber NU; Warmuth-Metz M; Deinlein F; Zwiener I; Faldum A; Fleischhack G; Benesch M; Krauss J; Kuehl J; Kortmann RD; Rutkowski S
    Neuro Oncol; 2011 Jun; 13(6):669-79. PubMed ID: 21636711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [High-dose chemotherapy in relapse of medulloblastoma in young children].
    Dupuis-Girod S; Hartmann O; Benhamou E; Doz F; Mechinaud F; Bouffet E; Coze C; Kalifa C
    Bull Cancer; 1997 Mar; 84(3):264-72. PubMed ID: 9207872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.